Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 338

1.

Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity.

Li CJ, Li J, Zhang QM, Lv L, Chen R, Lv CF, Yu P, Yu DM.

Cardiovasc Diabetol. 2012 Nov 15;11:142. doi: 10.1186/1475-2840-11-142.

PMID:
23153177
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.

Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.

Clin Ther. 2007 Nov;29(11):2374-84.

PMID:
18158078
[PubMed - indexed for MEDLINE]
3.

Long-term effectiveness and safety of liraglutide in clinical practice.

Ponzani P.

Minerva Endocrinol. 2013 Mar;38(1):103-12.

PMID:
23435446
[PubMed - indexed for MEDLINE]
4.

Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes.

Kaku K, Rasmussen MF, Clauson P, Seino Y.

Diabetes Obes Metab. 2010 Apr;12(4):341-7. doi: 10.1111/j.1463-1326.2009.01194.x.

PMID:
20380655
[PubMed - indexed for MEDLINE]
5.

The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements.

Lane W, Weinrib S, Rappaport J.

Diabetes Technol Ther. 2011 May;13(5):592-5. doi: 10.1089/dia.2010.0221. Epub 2011 Mar 15.

PMID:
21406014
[PubMed - indexed for MEDLINE]
6.

Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes.

Fujishima Y, Maeda N, Inoue K, Kashine S, Nishizawa H, Hirata A, Kozawa J, Yasuda T, Okita K, Imagawa A, Funahashi T, Shimomura I.

Cardiovasc Diabetol. 2012 Sep 14;11:107.

PMID:
22973968
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.

Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR; NN2211-1310 International Study Group.

Diabetes Care. 2004 Jun;27(6):1335-42.

PMID:
15161785
[PubMed - indexed for MEDLINE]
8.

Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits.

Nauck M, Marre M.

Postgrad Med. 2009 May;121(3):5-15. doi: 10.3810/pgm.2009.05.1997.

PMID:
19491535
[PubMed - indexed for MEDLINE]
9.

Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study.

Hong ES, Khang AR, Yoon JW, Kang SM, Choi SH, Park KS, Jang HC, Shin H, Walford GA, Lim S.

Diabetes Obes Metab. 2012 Sep;14(9):795-802. doi: 10.1111/j.1463-1326.2012.01600.x. Epub 2012 Apr 18.

PMID:
22443183
[PubMed - indexed for MEDLINE]
10.

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L; LEAD-6 Study Group.

Lancet. 2009 Jul 4;374(9683):39-47. doi: 10.1016/S0140-6736(09)60659-0. Epub 2009 Jun 8.

PMID:
19515413
[PubMed - indexed for MEDLINE]
11.

Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial(*).

Yang W, Chen L, Ji Q, Liu X, Ma J, Tandon N, Bhattacharyya A, Kumar A, Kim KW, Yoon KH, Bech OM, Zychma M.

Diabetes Obes Metab. 2011 Jan;13(1):81-8. doi: 10.1111/j.1463-1326.2010.01323.x.

PMID:
21114607
[PubMed - indexed for MEDLINE]
12.
13.

Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus.

Suzuki D, Toyoda M, Kimura M, Miyauchi M, Yamamoto N, Sato H, Tanaka E, Kuriyama Y, Miyatake H, Abe M, Umezono T, Fukagawa M.

Intern Med. 2013;52(10):1029-34. Epub 2013 May 15.

PMID:
23676586
[PubMed - indexed for MEDLINE]
Free Article
14.

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M, Blonde L; LEAD-4 Study Investigators.

Diabetes Care. 2009 Jul;32(7):1224-30. doi: 10.2337/dc08-2124. Epub 2009 Mar 16. Erratum in: Diabetes Care. 2010 Mar;33(3):692.

PMID:
19289857
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.

Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, Parikh S; Dapagliflozin 006 Study Group.

Ann Intern Med. 2012 Mar 20;156(6):405-15. doi: 10.7326/0003-4819-156-6-201203200-00003.

PMID:
22431673
[PubMed - indexed for MEDLINE]
16.

Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies.

Bode BW, Brett J, Falahati A, Pratley RE.

Am J Geriatr Pharmacother. 2011 Dec;9(6):423-33. doi: 10.1016/j.amjopharm.2011.09.007. Epub 2011 Nov 4.

PMID:
22055210
[PubMed - indexed for MEDLINE]
17.

One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target.

Rosenstock J, Rodbard HW, Bain SC, D'Alessio D, Seufert J, Thomsen AB, Svendsen CB, DeVries JH; Liraglutide-Detemir Study Group.

J Diabetes Complications. 2013 Sep-Oct;27(5):492-500. doi: 10.1016/j.jdiacomp.2013.04.008. Epub 2013 Jun 6.

PMID:
23746555
[PubMed - indexed for MEDLINE]
Free Article
18.

Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes.

Seino Y, Rasmussen MF, Nishida T, Kaku K.

Curr Med Res Opin. 2010 May;26(5):1013-22. doi: 10.1185/03007991003672551.

PMID:
20199137
[PubMed - indexed for MEDLINE]
19.

Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study.

Raz I, Stranks S, Filipczak R, Joshi P, Lertoft B, Rastam J, Chow CC, Shaban J.

Clin Ther. 2005 Sep;27(9):1432-43.

PMID:
16291416
[PubMed - indexed for MEDLINE]
20.

[Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin].

Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, Parikh S; Studiengruppe Dapagliflozin 006.

Dtsch Med Wochenschr. 2013 Apr;138 Suppl 1:S27-38. doi: 10.1055/s-0032-1305284. Epub 2013 Mar 25. German.

PMID:
23529568
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk